• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION SYNERGY; BIODEGRADABLE POLYMER DRUG ELUTING CORONARY STENT SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION SYNERGY; BIODEGRADABLE POLYMER DRUG ELUTING CORONARY STENT SYSTEM Back to Search Results
Model Number 10601
Device Problem Obstruction of Flow (2423)
Patient Problems Dyspnea (1816); Myocardial Infarction (1969); Restenosis (4576)
Event Date 04/13/2023
Event Type  Injury  
Manufacturer Narrative
A1: patient identifier: (b)(6).
 
Event Description
Evolve_lv_clv clinical stud.It was reported that myocardial infarction and in-stent restenosis (isr) occurred.On (b)(6) 2021, the subject presented with stable angina and was referred for cardiac catheterization.The target lesion was located in the proximal left anterior descending artery (lad) with 80% stenosis and was 16 mm long with a reference vessel diameter of 5.3 mm and timi flow of 3.The target lesion was treated with pre-dilation and placement of a 4.00 mm x 20 mm study stent.Following post-dilation, residual stenosis was 0% with timi flow of 3.In addition, a non-target lesion located in mid lad extending to distal lad was treated with placement of a 2.50 mm x 16 mm synergy drug eluting stent (des).A second non-target lesion located in 1st diagonal artery was treated with a 2.25 mm x 12 mm synergy des.The subject was discharged on aspirin and clopidogrel.On (b)(6) 2023, the subject presented in the emergency department (ed) with pressure-like substernal chest pain radiating to bilateral arms and lasting 40 minutes in duration with associated shortness of breath.The subject took nitroglycerine which did not provide complete pain relief and paramedics had given the subject 324mg of aspirin during transport to the ed.Cardiac enzymes were found to be elevated and electrocardiography revealed av-paced rhythm, st depression and t wave inversion in lateral leads with no clear ischemic changes or notable ectopy.The subject was diagnosed with non-q wave myocardial infarction and underwent several diagnostic tests.A chest x-ray revealed mild cardiomegaly, no focal consolidation or pulmonary edema, no pleural effusion or pneumothorax, and no acute pulmonary disease.Transthoracic echocardiography (tte) revealed markedly dilated left ventricle, mild left ventricular hypertrophy (lvh), severely decreased lv systolic function with lv ejection fraction of 15-20% with severe global hypokinesis, mild mitral regurgitation, and mild to moderate aortic insufficiency.The subject was hospitalized on the same day and started on heparin, gtt, aspirin, atrovastatin, plavix, and metropropol.The next day the subject underwent coronary angiography and, given the degree of multivessel progression, the subject was transferred to another hospital for complex percutaneous coronary intervention (pci) vs coronary artery bypass graft (cabg) evaluation.The subject was evaluated and deemed too high risk for surgery.On (b)(6) 2023, the 90% isr in the proximal lad was treated with balloon dilation using a 3.25mm non-compliant (nc) balloon from the left main coronary artery (lmca) into the lad followed by placement of a 4mm x 15mm non-boston scientific drug eluting stent from the mid lcma into the proximal lad.Following post dilation with a 4mm nc balloon, the final residual stenosis was noted to be 0% with timi flow 3.The event was considered resolved and the subject was discharged on dual antiplatelet therapy.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNERGY
Type of Device
BIODEGRADABLE POLYMER DRUG ELUTING CORONARY STENT SYSTEM
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
300 boston scientific way
marlborough MA 01752
Manufacturer (Section G)
BOSTON SCIENTIFIC CORPORATION
ballybrit business park
galway
EI  
Manufacturer Contact
rachel shields
4100 hamline ave n
arden hills, MN 55112
6512422111
MDR Report Key17780482
MDR Text Key323827693
Report Number2124215-2023-48637
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)Y
Reporter Country CodeUS
PMA/PMN Number
P150003
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Study,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 09/20/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received09/20/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date02/19/2022
Device Model Number10601
Device Catalogue Number10601
Device Lot Number0025260514
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received08/30/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured02/20/2020
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age71 YR
Patient SexMale
Patient RaceWhite
-
-